JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Akciju saraksts・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

21.95 -2.4

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

21.69

Max

Galvenie mērījumi
By Trading Economics
Ienākumi	202M 274M
Pārdošana	5.4M 284M
P/E Sektora vidējais	9.696 67.147
Peļņas marža	96.33
Darbinieki	796
EBITDA	-21M 26M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+40.49% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 6. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-366M 3.8B
Iepriekšējā atvēršanas cena	24.35
Iepriekšējā slēgšanas cena	21.95

Ziņu noskaņojums

By Acuity

28%

72%

79 / 347 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

14.845 / N/A Atbalsts un pretestība

ACADIA Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 1. maijs 21:36 UTC

Iegādes, apvienošanās, pārņemšana

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

2026. g. 1. maijs 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

2026. g. 1. maijs 18:37 UTC

Galvenie tirgus virzītāji

Senseonic Shares Slide on Underwritten Offering Price

2026. g. 1. maijs 16:46 UTC

Galvenie tirgus virzītāji

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2026. g. 1. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 1. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 1. maijs 20:42 UTC

Peļņas

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

2026. g. 1. maijs 19:33 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 1. maijs 19:33 UTC

Tirgus saruna

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

2026. g. 1. maijs 19:18 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

2026. g. 1. maijs 19:13 UTC

Tirgus saruna

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

2026. g. 1. maijs 18:36 UTC

Peļņas

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

2026. g. 1. maijs 18:35 UTC

Peļņas

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

2026. g. 1. maijs 18:28 UTC

Peļņas

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

2026. g. 1. maijs 18:27 UTC

Tirgus saruna

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

2026. g. 1. maijs 18:14 UTC

Iegādes, apvienošanās, pārņemšana

Barclays Completes Acquisition of Best Egg

2026. g. 1. maijs 18:04 UTC

Peļņas

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

2026. g. 1. maijs 17:43 UTC

Tirgus saruna

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

2026. g. 1. maijs 17:37 UTC

Tirgus saruna

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

2026. g. 1. maijs 17:30 UTC

Tirgus saruna

Peļņas

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

2026. g. 1. maijs 17:28 UTC

Tirgus saruna

Peļņas

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

2026. g. 1. maijs 17:21 UTC

Tirgus saruna

Peļņas

Apple Seen Absorbing Higher Memory Costs -- Market Talk

2026. g. 1. maijs 17:19 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

2026. g. 1. maijs 16:38 UTC

Tirgus saruna

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

2026. g. 1. maijs 16:23 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

2026. g. 1. maijs 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 1. maijs 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 1. maijs 16:15 UTC

Peļņas

This AI Stock Is Up 78% This Year. Why It Still Looks Like a Buy. -- Barrons.com

2026. g. 1. maijs 16:11 UTC

Tirgus saruna

Bank of Canada Committed a 'Messaging Blunder' -- Market Talk

2026. g. 1. maijs 16:04 UTC

Peļņas

Exxon Stock Slips. CEO Warns 'Full Impact' of War is Coming. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

ACADIA Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

40.49% augšup

Prognoze 12 mēnešiem

Vidējais 31.54 USD 40.49%

Augstākais 40 USD

Zemākais 23 USD

Pamatojoties uz 15 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi ACADIA Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

15 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 15 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam ACADIA Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

14.845 / N/AAtbalsts un pretestība

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

79 / 347 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.